BTIG Research Lowers Boston Scientific (NYSE:BSX) Price Target to $60.00

Boston Scientific (NYSE:BSX) had its price target cut by investment analysts at BTIG Research from $65.00 to $60.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the medical equipment provider’s stock. BTIG Research’s target price points to a potential upside of 29.99% from the company’s current price.

Other research analysts have also recently issued research reports about the company. Royal Bank Of Canada cut their price objective on Boston Scientific from $100.00 to $85.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Canaccord Genuity Group cut their target price on Boston Scientific from $71.00 to $70.00 and set a “buy” rating on the stock in a research report on Monday, June 1st. Barclays reduced their target price on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a report on Thursday, May 28th. Truist Financial dropped their price target on Boston Scientific from $64.00 to $62.00 and set a “buy” rating on the stock in a research note on Thursday, July 16th. Finally, Piper Sandler restated an “overweight” rating and set a $65.00 price objective on shares of Boston Scientific in a report on Friday, June 12th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $78.20.

Boston Scientific Price Performance

NYSE BSX traded up $0.10 on Wednesday, reaching $46.16. The company’s stock had a trading volume of 35,514,233 shares, compared to its average volume of 18,207,451. Boston Scientific has a twelve month low of $42.20 and a twelve month high of $109.50. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. The firm’s 50 day moving average is $46.78 and its two-hundred day moving average is $63.10. The stock has a market cap of $68.61 billion, a PE ratio of 19.32, a PEG ratio of 0.87 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.36 billion. During the same quarter in the previous year, the company posted $0.75 EPS. The business’s revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, sell-side analysts predict that Boston Scientific will post 3.35 EPS for the current year.

Boston Scientific declared that its Board of Directors has approved a share buyback plan on Monday, May 18th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.

Insider Buying and Selling at Boston Scientific

In related news, Director David C. Habiger purchased 2,250 shares of the company’s stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average cost of $55.92 per share, with a total value of $125,820.00. Following the completion of the purchase, the director owned 13,878 shares of the company’s stock, valued at $776,057.76. The trade was a 19.35% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Cheryl Pegus bought 1,770 shares of the company’s stock in a transaction on Wednesday, May 20th. The stock was purchased at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the transaction, the director owned 1,770 shares in the company, valued at approximately $99,987.30. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have purchased 9,800 shares of company stock worth $554,012. 0.34% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Cary Street Partners Financial LLC boosted its holdings in shares of Boston Scientific by 16.7% during the 2nd quarter. Cary Street Partners Financial LLC now owns 25,092 shares of the medical equipment provider’s stock worth $1,071,000 after buying an additional 3,597 shares during the period. Farther Finance Advisors LLC increased its holdings in shares of Boston Scientific by 28.9% during the 2nd quarter. Farther Finance Advisors LLC now owns 28,699 shares of the medical equipment provider’s stock worth $1,227,000 after purchasing an additional 6,427 shares during the period. Sequoia Financial Advisors LLC raised its position in shares of Boston Scientific by 2.3% during the second quarter. Sequoia Financial Advisors LLC now owns 49,355 shares of the medical equipment provider’s stock valued at $2,106,000 after buying an additional 1,119 shares during the last quarter. Simplify Asset Management Inc. grew its position in Boston Scientific by 32.6% during the second quarter. Simplify Asset Management Inc. now owns 15,014 shares of the medical equipment provider’s stock worth $641,000 after buying an additional 3,690 shares in the last quarter. Finally, Riversedge Advisors LLC bought a new position in Boston Scientific during the second quarter valued at about $320,000. 89.07% of the stock is owned by institutional investors.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported adjusted second-quarter EPS of $0.86, above the $0.83 analyst consensus and up from $0.75 a year earlier. Revenue rose 7.5% to $5.442 billion, exceeding expectations of roughly $5.36-$5.37 billion. Boston Scientific beats second quarter expectations, raises full-year outlook
• Positive Sentiment: Growth was broad-based, with Cardiovascular sales up 8.3%, MedSurg sales up 5.9%, and particularly strong reported growth in APAC and LACA. Margin expansion also supported the quarterly result. Boston Scientific Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: The company completed its previously announced $2 billion accelerated share repurchase, buying back approximately 40 million shares. Boston Scientific also invested $1.5 billion in MiRus and received FDA clearance for its TruSelect 2.6 Microcatheter, supporting its longer-term product pipeline. Boston Scientific announces results for second quarter 2026
• Neutral Sentiment: Boston Scientific maintained a constructive sales-growth outlook, projecting full-year reported revenue growth of approximately 5.5% to 6.5%. Nevertheless, its $21.2-$21.4 billion revenue forecast remains below the $21.6 billion consensus estimate.
• Negative Sentiment: The company lowered full-year adjusted EPS guidance to $3.28-$3.32 from $3.34-$3.41, below the $3.36 consensus. Third-quarter EPS guidance of $0.80-$0.82 and revenue guidance of $5.2-$5.3 billion also trail analyst expectations. Boston Scientific trims annual profit forecast on softer Watchman device demand
• Negative Sentiment: Management cited slowing demand for the Watchman heart device and competitive pressure. A restructuring program expected to cost $700 million-$800 million, with potential headcount reductions through 2029, is also weighing on near-term earnings, although it is intended to generate future savings. Boston Scientific Cuts Outlook Ahead of Restructuring

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.